▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1816 by analyst upside · 2026-09-27
IDYA
IDEAYA Biosciences, Inc.
Healthcare · Market Cap $4B · P/E 0x
ANALYST PRICE TARGET
+42.8%
implied upside to consensus target
Current Price $36.69
Consensus Target $52.38
Bull Target $65.0
Bear Target $31.0
Analysts Covering 13
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
10
Hold
1
Sell
0
52-Week Low $26.05
52-Week High $42.68
YTD Return +8.4%
FUNDAMENTALS
Market Cap $4B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.92
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $234M
Profit Margin -74.8%
52-WEEK RANGE
52-Week Low $26.05
52-Week High $42.68
Current Price $36.69
Bear Target $31.0
Bull Target $65.0
● Now $36.69 ● Target $52.38
TRADING DATA
Avg Volume 858K
YTD Return +8.4%
Analyst Count 13
Consensus Buy
Upside to Target +42.8%
Last Updated 2026-09-27

ANALYST SUMMARY

IDEAYA Biosciences, Inc. (IDYA) is currently trading at $36.69 with a Wall Street consensus price target of $52.38, implying potential upside of 42.8% over the next 12 months. 13 analysts currently cover IDYA, with a consensus rating of Buy - 93% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $65.0, while the most cautious has a target of $31.0.

IDYA operates in the Healthcare sector with a market capitalisation of $4B. The stock is up 8.4% year-to-date and is currently trading near the upper end of its 52-week range of $26.05 – $42.68.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ACAD +55.5%
Acadia Pharmaceuticals Inc.
$4B · P/E 9.3x · Buy
INDV +36.8%
Indivior Pharmaceuticals, Inc.
$4B · P/E 12.8x · Buy
OPCH +23.9%
Option Care Health, Inc.
$3B · P/E 17.5x · Buy
AVAH +17.6%
Aveanna Healthcare Holdings Inc.
$3B · P/E 9.8x · Buy
GRFS +47.8%
Grifols, S.A.
$5B · P/E 9.7x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for IDYA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Guggenheim - Reiterated
Buy → Buy 2026-09-09 62% win rate (8 calls)
Citizens reit
Market Outperform → Market Outperform 2026-09-01 Building track record
Truist Securities - Reiterated
Buy → Buy 2026-08-05 Building track record
Wedbush - Reiterated
Outperform → Outperform 2026-08-05 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-07-07 Building track record
Truist Securities - Reiterated
Buy → Buy 2026-07-07 Building track record
Wedbush reit
Outperform → Outperform 2026-06-12 Building track record
Wedbush reit
Outperform → Outperform 2026-06-02 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
53
out of 100
Coverage depth
20/30
Consensus clarity
11/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →